Blood culture and antimicrobial susceptibility pattern of bacteria and fungi isolated from febrile neutropenic patients treated with chemotherapy at Taleghani hospital, Tehran
Abstract
Background and Objectives: The aim of this study was to determine the drug susceptibility pattern of the pathogens causing bacteraemia and fungemia in patients who have developed febrile neutropenia after chemotherapy.
Materials and Methods: A total of 95 patients with suspected or proven malignancy (50 patients) were admitted to the adult haematology ward at Taleghani Hospital in Tehran. Blood samples were inoculated into the bottles of Bact/Alert blood culture system and sent to Payvand’s clinical and special laboratory immediately and then incubated at 35 ± 2°C. Culture from positive bottles were plated on appropriate media and incubated at 37°C and 30°C for bacterial and fungal isolation, respectively. A bacterial suspension with turbidity equal to 0.5 McFarland (1.5 × 108 CFU/mL) was prepared and used for the Vitec2 system (biomerioux). Statistical analysis using independent Fisher’s exact test was conducted and a p-value of < 0.05 was considered as significant.
Results: Among 50 patients with approved malignancy, Acute Lymphoblastic Leukaemia (ALL) and Acute Myeloid Leukaemia (AML) were the most common underlying diseases. This study showed, 20% (n: 10) of febrile neutropenic episodes established positive blood culture. Of them, 3 were Gram-negative (30%) and 5 were-Gram-positive bacteria (50%) and 2 patients (20%) showed fungemia with Fusarium spp.
Conclusion: It is crucial to know about the likely pathogens and their local antibiotic and antifungal sensitivity patterns. Such local findings will show if any modifications to treatment guidelines are necessary.
2. Viscoli C, Varnier O, Machetti M. Infections in patients with febrile neutropenia: epidemiology, microbiology, and risk stratification. Clin Infect Dis 2005; 40: S240-245.
3. Akova M. Emerging problem pathogens: A review of resistance patterns over time. Int J Infect Dis 2006;10:53-58.
4. Wisplinghoff H, Seifert H, Wenzel RP, Edmond MB. Current trends in the epidemiology of nosocomial bloodstream infections in patients with hematological malignancies and solid neoplasms in hospitals in the United States. Clin Infect Dis 2003;36:1103-1110.
5. Cruciani M, Rampazzo R, Malena M, Lazzarini L, Todeschini G, Messori A, et al. Prophylaxis with fluoroquinolones for bacterial infections in neutropenic patients: a meta-analysis. Clin Infect Dis 1996; 23: 795-805.
6. Press OW, Ramsey PG, Larson EB, Fefer A, Hickman RO. Hickman catheter infections in patients with malignancies. Medicine (Baltimore) 1984; 63:189-200.
7. Nucci M, Anaissie E. Cutaneous infection by Fusarium species in healthy and immunocompromised hosts: implications for diagnosis and management. Clin Infect Dis 2002; 35: 909-920.
8. Jossi M, Ambrosioni J, Macedo-Vinas M, Garbino J. Invasive fusariosis with prolonged fungemia in a patient with acute lymphoblastic leukemia: case report and review of the literature. Int J Infect Dis 2010; 14: e354-356.
9. Mikulska M, Furfaro E, Del Bono V, Gualandi F, Raiola AM, Molinari MP, et al. Galactomannan testing might be useful for early diagnosis of fusariosis. Diagn Microbiol Infect Dis 2012; 72: 367-369.
10. Tortorano AM, Esposto MC, Prigitano A, Grancini A, Ossi C, Cavanna C, et al. Cross-reactivity of Fusarium spp. in the Aspergillus Galactomannan enzyme-linked immunosorbent assay. J Clin Microbiol 2012; 50:1051-1053.
11. Clinical & Laboratory Standards Institute. M100 Performance Standards for Antimicrobial Susceptibility Testing A CLSI supplement for global application 2018.
12. Alshahni MM, Makimura K, Yamada T, Satoh K, Ishihara Y, Takatori K, et al. Direct colony PCR of several medically important fungi using Ampdirect plus. Jpn J Infect Dis 2009; 62:164-167.
13. Clinical and Laboratory Standards Institute (CLSI). Document M38-A2. Reference Method Broth Dilution Antifung Susceptibility Test of Filamentous Fungi 2008; 28:1-35.
14. Diekema DJ, Messer SA, Hollis RJ, Jones RN, Pfaller MA. Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi. J Clin Microbiol 2003; 41: 3623-3626.
15. Ritchie S, Palmer S, Ellis-Pegler R. High-risk febrile neutropenia in Auckland 2003-2004: the influence of the microbiology laboratory on patient treatment and the use of pathogen-specific therapy. Intern Med J 2007; 37: 26-31.
16. Klastersky J, Ameye L, Maertens J, Georgala A, Muanza F, Aoun M, et al. Bacteraemia in febrile neutropenic cancer patients. Int J Antimicrob Agents 2007; 30: S51-59.
17. Oude Nijhuis CSM, Daenen SMGJ, Vellenga E, van der Graaf WTA, Gietema JA, Groen HJM, et al. Fever and neutropenia in cancer patients: the diagnostic role of cytokines in risk assessment strategies. Crit Rev Oncol Hematol 2002; 44: 163-174.
18. Latif S, Anwar MS, Ahmad I. Bacterial pathogens responsible for blood stream infection (Bsi) and pattern of drug resistance in a tertiary care hospital of Lahore. Biomedica 2009; 25: 101-105.
19. Muhammed M, Anagnostou T, Desalermos A, Kourkoumpetis TK, Carneiro HA, Glavis-Bloom J, et al. Fusarium infection: report of 26 cases and review of 97 cases from the literature. Medicine (Baltimore) 2013; 92: 305-316.
20. Horn DL, Freifeld AG, Schuster MG, Azie NE, Franks B, Kauffman CA. Treatment and outcomes of invasive fusariosis: review of 65 cases from the PATH Alliance ® registry. Mycoses 2014; 57: 652-658.
Files | ||
Issue | Vol 11 No 2 (2019) | |
Section | Original Article(s) | |
DOI | https://doi.org/10.18502/ijm.v11i2.1067 | |
Keywords | ||
Febrile neutropenia Blood culture Chemotherapy Fungemia Cancer |
Rights and permissions | |
![]() |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |